Related Experiment Video
Updated: Aug 14, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)
Michaela Scherr1, Anuhar Chaturvedi, Karin Battmer
1Medizinische Hochschule Hannover, Zentrum Innere Medizin, Abteilung Hämatologie, Hämostaseologie und Onkologie, Carl-Neuberg Strasse 1, D-30623 Hannover, Germany. m.scherr@t-online.de
Abstract:
Although targeting the BCR-ABL tyrosine kinase activity by imatinib mesylate has rapidly become first-line therapy in chronic myeloid leukemia (CML), drug resistance suggests that combination therapy directed to a complementing target may significantly improve treatment results. To identify such potential targets, we used lentivirus-mediated RNA interference (RNAi) as a tool for functional genomics in cell lines as well as primary normal and CML CD34+ cells. In a conditional cell culture model, we demonstrate that RNAi-mediated reduction of SHP2, STAT5, and Gab2 protein expression inhibits BCR-ABL-dependent but not cytokine-dependent proliferation in a dose-dependent manner. Similarly, colony formation of purified primary CML but not of normal CD34+ colony-forming cells is specifically reduced by inhibition of SHP2, STAT5, and Gab2 expression, respectively. In addition, coexpression of both anti-BCR-ABL and anti-SHP2 shRNAs from a single lentiviral vector induces stronger inhibition of colony formation as compared to either shRNA alone. The data indicate that BCR-ABL expression may affect the function of normal signaling molecules. Targeting these molecules may harbor significant therapeutic potential for the treatment of patients with CML.
Insights
Targeting SHP2, STAT5, and Gab2 with RNA interference (RNAi) can inhibit chronic myeloid leukemia (CML) cell growth. Combination therapy targeting BCR-ABL and SHP2 shows enhanced inhibition, suggesting new therapeutic strategies for CML.
Area of Science:
- Hematology
- Molecular Biology
- Genomics
Background:
- Imatinib mesylate is a first-line therapy for chronic myeloid leukemia (CML).
- Drug resistance necessitates combination therapies targeting complementary pathways.
- Functional genomics can identify novel therapeutic targets in CML.
Purpose of the Study:
- To identify potential therapeutic targets for CML beyond BCR-ABL.
- To investigate the role of SHP2, STAT5, and Gab2 in BCR-ABL-dependent CML proliferation.
- To evaluate combination therapy targeting BCR-ABL and SHP2.
Main Methods:
- Lentivirus-mediated RNA interference (RNAi) for functional genomics.
- Utilized cell lines and primary normal and CML CD34+ cells.
- Conditional cell culture models and colony formation assays.
Main Results:
- RNAi-mediated reduction of SHP2, STAT5, and Gab2 inhibited BCR-ABL-dependent proliferation.
- Colony formation of CML CD34+ cells was specifically reduced by inhibiting SHP2, STAT5, and Gab2.
- Coexpression of anti-BCR-ABL and anti-SHP2 shRNAs showed stronger inhibition than single shRNAs.
Conclusions:
- SHP2, STAT5, and Gab2 are potential therapeutic targets in CML.
- Targeting these molecules may overcome imatinib resistance.
- Combination therapy targeting BCR-ABL and SHP2 demonstrates significant therapeutic potential for CML treatment.
